Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance

Sigurdur Yngvi Kristinsson*, Magnus Björkholm, Sam Schulman, Ola Landgren

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)

Abstract

Patients with multiple myeloma are at an increased risk of venous thromboembolism (VTE), especially when treated with the immunomodulatory drugs, thalidomide and lenalidomide, in combination with dexamethasone and/or chemotherapy. Several studies have shown that patients with multiple myeloma precursor disease (monoclonal gammopathy of undetermined significance [MGUS]) also have a higher risk of thrombosis compared to the general population. The underlying mechanisms for the hypercoagulable state are not completely understood. In this review, we discuss risk factors for thrombosis in multiple myeloma, as well as prophylactic strategies, the evidence for thrombosis among patients with MGUS, and proposed mechanisms for the hypercoagulability.

Original languageEnglish
Pages (from-to)46-54
Number of pages9
JournalSeminars in Hematology
Volume48
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Dive into the research topics of 'Hypercoagulability in multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance'. Together they form a unique fingerprint.

Cite this